World Investment Advisors Purchases Shares of 1,174 Bio-Rad Laboratories, Inc. (NYSE:BIO)

World Investment Advisors bought a new stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,174 shares of the medical research company's stock, valued at approximately $286,000.

Several other hedge funds have also recently added to or reduced their stakes in BIO. GeoWealth Management LLC lifted its stake in Bio-Rad Laboratories by 342.9% in the fourth quarter. GeoWealth Management LLC now owns 93 shares of the medical research company's stock valued at $31,000 after buying an additional 72 shares during the period. Picton Mahoney Asset Management lifted its stake in Bio-Rad Laboratories by 55.6% in the fourth quarter. Picton Mahoney Asset Management now owns 98 shares of the medical research company's stock valued at $32,000 after buying an additional 35 shares during the period. Curat Global LLC acquired a new position in Bio-Rad Laboratories in the first quarter valued at about $34,000. Brown Brothers Harriman & Co. raised its position in shares of Bio-Rad Laboratories by 2,928.6% during the fourth quarter. Brown Brothers Harriman & Co. now owns 212 shares of the medical research company's stock worth $70,000 after purchasing an additional 205 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in shares of Bio-Rad Laboratories during the fourth quarter worth about $71,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Down 1.0%

Shares of NYSE:BIO traded down $2.54 during mid-day trading on Friday, reaching $257.34. 298,849 shares of the stock were exchanged, compared to its average volume of 346,735. The company has a quick ratio of 4.43, a current ratio of 5.99 and a debt-to-equity ratio of 0.18. The company has a market cap of $7.00 billion, a P/E ratio of -3.38 and a beta of 0.95. Bio-Rad Laboratories, Inc. has a one year low of $211.43 and a one year high of $387.99. The stock's 50 day simple moving average is $237.15 and its 200-day simple moving average is $269.16.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.73 by $0.81. The business had revenue of $585.40 million during the quarter, compared to the consensus estimate of $573.01 million. Bio-Rad Laboratories had a positive return on equity of 4.32% and a negative net margin of 85.16%. Bio-Rad Laboratories's quarterly revenue was down 4.2% on a year-over-year basis. During the same period last year, the company earned $2.30 earnings per share. As a group, equities research analysts predict that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on BIO. Royal Bank Of Canada dropped their price target on Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating on the stock in a research report on Friday, May 2nd. UBS Group dropped their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen raised Bio-Rad Laboratories from a "hold" rating to a "buy" rating in a research report on Saturday, July 5th. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $260.00 to $245.00 and set an "equal weight" rating on the stock in a research report on Monday, June 9th. Finally, Citigroup dropped their price target on Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $324.25.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.